United States - English - NLM (National Library of Medicine)

teva women's health, inc. - trimipramine maleate (unii: 269k6498ld) (trimipramine - unii:6s082c9ndt) - trimipramine 25 mg - surmontil is indicated for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. in studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. in hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. the use of maois intended to treat psychiatric disorders with surmontil or within 14 days of stopping treatment with surmontil is contraindicated because of an increased risk of serotonin syndrome. the use of surmontil within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting surmontil in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - trimipramine maleate -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - trimipramine maleate 69.75mg equivalent to 50 mg trimipramine base;   - capsule - 50 mg - active: trimipramine maleate 69.75mg equivalent to 50 mg trimipramine base   excipient: colloidal silicon dioxide indigo carmine iron oxide yellow magnesium stearate maize starch microcrystalline cellulose titanium dioxide - indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation is a presenting symptom. sleep disturbance is controlled within 24 hours and true anti-depressant action follows within 7-10 days.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - trimipramine - film-coated tablet - 25 milligram(s) - non-selective monoamine reuptake inhibitors; trimipramine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - trimipramine maleate - oral capsule - 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - trimipramine - film-coated tablet - non-selective monoamine reuptake inhibitors; trimipramine

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - trimipramine maleate - capsule, hard - 50 milligram(s) - non-selective monoamine reuptake inhibitors; trimipramine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - trimipramine maleate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - trimipramine maleate - oral capsule - 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - trimipramine maleate - capsule, hard - non-selective monoamine reuptake inhibitors; trimipramine